At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- NBI-1117570 (drug), Placebo (drug)
- How long the study runs
- Study runs about 18 months (dates as stated)
- About the drug or intervention
- NBI-1117570 — drug: Oral administration · Placebo — drug: Oral administration
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 55 Years
- Who
- All
- Number of participants
- 120
- Started
- 2026-02-16
- Last checked
- 2026-07
Plain English Summary
What is this study?
- • Testing a new treatment for schizophrenia
- • Phase2 - 120 participants
- • The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization
Who can take part?
- • Ages 18 Years to 55 Years
- • Diagnosed with schizophrenia
Where?
- • London - Neurocrine Clinical Site
- • Oxford - Neurocrine Clinical Site
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.
Schizophrenia
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 55 Years
- Who can join: All genders
Biomarkers mentioned
had a positive
Treatment history
Treatments you must have had:
- ✓ hospitalization
What the study is looking for
- ✓18 to 55 years of age
- ✓Primary diagnosis of schizophrenia ≥1 year before screening.
- ✓Participant is experiencing an acute exacerbation or relapse of symptoms with onset less than 2 months before...
- ✓Participant must have had a positive response to at least 1 antipsychotic therapy (other than clozapine) for the...
Who cannot take part
- ✗Considered to be at imminent risk of suicide or injury to self or others.
- ✗History of epilepsy, seizures, or convulsions.
- ✗Currently taking prohibited medications.
- ✗Pregnant or lactating.
- ✗Note: Additional inclusion/exclusion criteria may apply, per protocol.
See the full criteria
Key Inclusion Criteria:
* 18 to 55 years of age
* Primary diagnosis of schizophrenia ≥1 year before screening.
* Participant is experiencing an acute exacerbation or relapse of symptoms with onset less than 2 months before screening and currently requires hospitalization.
* Participant must have had a positive response to at least 1 antipsychotic therapy (other than clozapine) for the treatment of a prior acute relapse.
Key Exclusion Criteria:
* Considered to be at imminent risk of suicide or injury to self or others.
* History of epilepsy, seizures, or convulsions.
* Has orthostatic hypotension, or history of pulmonary hypertension, obstructive coronary artery disease, hypertrophic cardiomyopathy, myocardial infarction, coronary artery revascularization, heart failure, left ventricular hypertrophy, moderate or severe cardiac valvopathy, or other cardiovascular conditions or measures that would preclude participation.
* Currently taking prohibited medications.
* Pregnant or lactating.
Note: Additional inclusion/exclusion criteria may apply, per protocol.
Where Is This Study? (2 UK sites)
Neurocrine Clinical Site
London SE5 8AZ, United Kingdom
Neurocrine Clinical Site
Oxford OX3 7JX, United Kingdom
How to Get in Touch
Neurocrine Medical Information Call Center
Sponsor contactCONTACT
1-877-641-3461 medinfo@neurocrine.com
Data sourced from ClinicalTrials.gov · Last verified: 2026-07